Sonntag, 18. April 2021
Navigation öffnen
Anzeige:
Prevymis
Prevymis
Fachinformation
JOURNAL ONKOLOGIE – STUDIE
SwissNET

SwissNET - a Registry for Neuroendocrine Tumours in Switzerland

Rekrutierend

NCT-Nummer:
NCT01039922

Studienbeginn:
Januar 2008

Letztes Update:
23.01.2020

Wirkstoff:
-

Indikation (Clinical Trials):
Neoplasms, Neuroendocrine Tumors, Carcinoid Tumor

Geschlecht:
Alle

Altersgruppe:
Alle

Phase:
-

Sponsor:
University Hospital Inselspital, Berne

Collaborator:
Cantonal Hospital of St. Gallen, University Hospital, Basel, Switzerland, University Hospital, Geneva, University of Lausanne Hospitals, University Hospital, Zürich, Triemlispital Zurich, Spitalnetz Bern, Ente Ospedaliero Cantonale, Bellinzona, Luzerner Kantonssp

Studienleiter

Aurel Perren, MD
Study Director
Institute of Pathology, University of Bern, Bern

Kontakt

Studienlocations
(3 von 55)

Bezirksspital Affoltern
Affoltern am Albis
SwitzerlandRekrutierend» Google-Maps
Istituto oncologico della Svizzera italiana
Bellinzona
SwitzerlandRekrutierend» Google-Maps
Div. of Endocrinology, Diabetes and Clinical Nutrition, Bern University Hospital
3010 Bern
SwitzerlandRekrutierend» Google-Maps
Private practise Dr. Mannhart
Churwalden
SwitzerlandRekrutierend» Google-Maps
Hôpitaux Universitaires de Genève
Geneva
SwitzerlandRekrutierend» Google-Maps
Centre hospitalier universitaire vaudois, CHUV
Lausanne
SwitzerlandRekrutierend» Google-Maps
Kantonsspital Münsterlingen
Münsterlingen
SwitzerlandRekrutierend» Google-Maps
Gesundheitszentrum Fricktal
Rheinfelden
SwitzerlandRekrutierend» Google-Maps
Centre hospitalier du centre du Valais
Sion
SwitzerlandRekrutierend» Google-Maps
Alle anzeigen

Studien-Informationen

Detailed Description:

Background

Gastroentero-pancreatic neuroendocrine tumours (GEP-NETs) are generally classified as rare diseases. Little is known about their cell biology and their mechanistic regulation. During the last years, the incidence of GEP-NETs is continuously increasing worldwide. In parallel, novel treatment options are currently evaluated which may substantially improve prognosis of patients with NETs. Data on such tumours in Switzerland, however, is scarce and treatment strategies vary throughout the country.

Objective

To systematically and prospectively collect clinical information of patients with GEP-NETs in Switzerland based on a histologically confirmed diagnosis.

Methods

All NETs of both, gastrointestinal and pulmonary origin are included provided that patients have given informed consent. Data will be entered prospectively and anonymised in a specifically designed database. Contributing centres and general practitioners are visited by a study nurse, patient files are analysed and data is transferred to the database. In case of conflicting evidence, questions are resolved in collaboration with a review board of SwissNET. Evaluation of treatment modalities and patient outcomes (e.g. mortality, hospitalisation rate) will take place within regular time frames.

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Neuroendocrine tumor irrespective of primary tumor location

- Diagnosis in Switzerland

- Given informed consent

Studien-Rationale

Primary outcome:

1. Tumor-related mortality (Time Frame - Every 5 years)



Secondary outcome:

1. Incidence of GEP-NET in Switzerland (Time Frame - Every 5 years)

2. Effect of specific treatment strategies (Time Frame - Every 5 years)

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren
Brustkrebs bei Männern
Brustkrebs+bei+M%C3%A4nnern
© Antonio Tanaka - stock.adobe.com

Jährlich erkranken zwischen 600 und 700 Männer an Brustkrebs. Das macht rund ein Prozent aller Brustkrebsfälle aus. Da es für Männer keine Brustkrebs-Früherkennungsprogramme gibt und der Gedanke an Krebs zunächst fern liegt, wird die Erkrankung beim Mann meist erst in späteren Stadien diagnostiziert als bei Frauen. Dadurch verstreicht wertvolle Zeit, die bei der Behandlung fehlt. Wie Brustkrebs beim Mann entsteht, erkannt und behandelt wird,...

Studie zu Online-Programm zur Stressreduktion ausgezeichnet
Studie+zu+Online-Programm+zur+Stressreduktion+ausgezeichnet
© Andrey Popov / fotolia.com

Der Reinhold-Schwarz-Förderpreis für Psychoonkologie 2018 wurde an die Psychologin Astrid Grossert-Leugger, Basel, verliehen. Die Preisträgerin erhielt die mit 2.500 € dotierte Auszeichnung für ihre Arbeit zum Thema „Web-Based Stress Management for Newly Diagnosed Patients with Cancer (STREAM): A Randomized, Wait‐List Controlled Intervention Study“. Die Preisverleihung erfolgte auf der 17. Jahrestagung der...